Where ancient botany meets PCR.
Our R&D team is concentrated on the most dreadful diseases confronting the world today. We have developed significant breakthroughs in treating HBV, HIV and HSV — and we measure them with the same assays used by any modern hospital.
Great molecules, poor absorption.
Many proven plant molecules fail clinically because of poor systemic absorption. Our unique extraction procedure yields high-degree bioavailability, combined with co-extracts that improve gut absorption — the phyto-nanoparticle approach behind every HOO-IMM formulation.
Phyto-nanoparticle extraction
Proprietary process that shrinks active fractions for faster uptake and sustained plasma levels.
Multi-target polyherbal design
Ten plant species act on different viral and host targets simultaneously — replication, antigen secretion, inflammation, immunity.
In-vitro & clinical validation
HBsAg secretion inhibition and HepG2 hepato-carcinoma studies, plus clinician reports from India and Africa.
Five ways the formulation attacks Hepatitis B.
What the literature says.
Biomarkers we track, per condition.
| Condition | Markers | Repeat |
|---|---|---|
| Hepatitis B | HBsAg ELISA · HBV DNA quantitative · ALT/AST · Anti-HBs | Every 2–3 months |
| HIV | HIV RNA viral load · CD4/CD8 · proviral DNA | Every 3 months |
| HSV | HSV DNA PCR · HSV IgG · HSV IgM | Months 4–6, then 8 |
| Liver | SGPT · SGOT · Bilirubin | Monthly |
| Thyroid | TSH · T3 · T4 | Every 3 months |
WHO recommends HBV DNA quantification in chronic HBV to determine phase, treatment and response.
Collaborate with us.
We welcome Ayush clinicians, pharmacists, hospitals and universities for clinical observation studies and distribution partnerships.